CLL
Conference Coverage
ONO-4059 delivered hit to relapsed/refractory CLL
Key clinical point: ONO-4059 induced responses in most patients with relapsed/refractory CLL, including those with a 17p deletion. Major finding:...
Conference Coverage
Idelalisib efficacy remains rock steady in relapsed CLL
Major finding: Idelalisib and rituximab significantly increased progression-free survival (HR, 0.18; P less than .0001). Data source: A...
Conference Coverage
Ibrutinib holds CLL at bay in majority of patients at 30 months
Major finding: At 30 months of follow-up, overall survival with ibrutinib monotherapy was 96.6% among patients with newly diagnosed chronic...
Conference Coverage
VIDEO: Ibrutinib boosts survival of relapsed/refractory CLL
Commentary
Drugs approved in 2013
News
FDA approves ofatumumab for chronic lymphocytic leukemia
News
Persistent lymphocytosis with ibrutinib does not indicate early relapse
Major finding: Patients with chronic lymphocytic leukemia who experienced persistent lymphocytosis associated with ibrutinib treatment did not...
News
Idelalisib and rituximab extends survival in CLL patients
Conference Coverage
ONO-4059 makes waves in heavily pretreated CLL
Major finding: The response rate was 89% overall and 71% for patients with 17p deletion. Data source: A prospective, phase I dose-escalation study...